New clinical opportunities for mineralocorticoid receptor antagonists: focus on antifibrotic effects

被引：0

作者：

Dragomiretskaya, Natalia A. ^{[1
]}

Tarzimanova, Aida, I ^{[1
]}

Kucherova, Julia S. ^{[1
]}

Podzolkov, Valery, I ^{[1
]}

机构：

[1] Sechenov First Moscow State Med Univ, Sechenov Univ, Moscow, Russia

来源：

TERAPEVTICHESKII ARKHIV | 2021年 / 93卷 / 09期

关键词：

aldosterone antagonists; Spironolactonum; antifibrotic effect; chronic heart failure; arterial hypertension; COVID-19; PRIMARY ALDOSTERONISM; HEART-FAILURE; CARDIOVASCULAR EVENTS; SPIRONOLACTONE; HYPERTENSION; DIAGNOSIS; FIBROSIS; SOCIETY;

D O I：

10.26442/00403660.2021.09.201016

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Mineralocorticoid receptor antagonists have been successfully used for many years to treat patients with primary hyperaldosteronism, refractory arterial hypertension and chronic heart failure. The increased interest in this drug in recent years is due to new information about its antifibrotic and antiproliferative effects, both cardiac and extracardiac. The article also discusses the possibility of using spironolactone in patients with the new coronavirus infection SARS-CoV-2 (COVID-19).

引用

页码：1132 / 1137

页数：6

共 43 条

[1]

[Anonymous], 2020, FOOD DRUG ADM CTR DR

[2] Spironolactone: An Anti-androgenic and Anti-hypertensive Drug That May Provide Protection Against the Novel Coronavirus (SARS-CoV-2) Induced Acute Respiratory Distress Syndrome (ARDS) in COVID-19 [J].

Cadegiani, Flavio A. ;

Wambier, Carlos G. ;

Goren, Andy .

FRONTIERS IN MEDICINE, 2020, 7

[3] Spironolactone inhibits endothelial-mesenchymal transition via the adenosine A2A receptor to reduce cardiorenal fibrosis in rats [J].

Chen, Xingxing ;

Ge, Wenhua ;

Dong, Tiancheng ;

Hu, Jie ;

Chen, Lingzhi ;

Fan, Xiaofang ;

Gong, Yongsheng ;

Zhou, Hao .

LIFE SCIENCES, 2019, 224 :177-186

[4] The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the heart 'OMics' in AGEing (HOMAGE) randomized clinical trial [J].

Cleland, John G. F. ;

Ferreira, Joao Pedro ;

Mariottoni, Beatrice ;

Pellicori, Pierpaolo ;

Cuthbert, Joe ;

Verdonschot, Job A. J. ;

Petutschnigg, Johannes ;

Ahmed, Fozia Z. ;

Cosmi, Franco ;

La Rocca, Hans-Peter Brunner ;

Mamas, Mamas A. ;

Clark, Andrew L. ;

Edelmann, Frank ;

Pieske, Burkert ;

Khan, Javed ;

McDonald, Ken ;

Rouet, Philippe ;

Staessen, Jan A. ;

Mujaj, Blerim ;

Gonzalez, Arantxa ;

Diez, Javier ;

Hazebroek, Mark ;

Heymans, Stephane ;

Latini, Roberto ;

Grojean, Stephanie ;

Pizard, Anne ;

Girerd, Nicolas ;

Rossignol, Patrick ;

Collier, Tim J. ;

Zannad, Faiez .

EUROPEAN HEART JOURNAL, 2021, 42 (06) :684-+

[5] Androgen Regulation of the TMPRSS2 Gene and the Effect of a SNP in an Androgen Response Element [J].

Clinckemalie, Liesbeth ;

Spans, Lien ;

Dubois, Vanessa ;

Laurent, Michael ;

Helsen, Christine ;

Joniau, Steven ;

Claessens, Frank .

MOLECULAR ENDOCRINOLOGY, 2013, 27 (12) :2028-2040

[6] Clinical Phenogroups in Heart Failure With Preserved Ejection Fraction Detailed Phenotypes, Prognosis, and Response to Spironolactone [J].

Cohen, Jordana B. ;

Schrauben, Sarah J. ;

Zhao, Lei ;

Basso, Michael D. ;

Cvijic, Mary Ellen ;

Li, Zhuyin ;

Yarde, Melissa ;

Wang, Zhaoqing ;

Bhattacharya, Priyanka T. ;

Chirinos, Diana A. ;

Prenner, Stuart ;

Zamani, Payman ;

Seiffert, Dietmar A. ;

Car, Bruce D. ;

Gordon, David A. ;

Margulies, Kenneth ;

Cappola, Thomas ;

Chirinos, Julio A. .

JACC-HEART FAILURE, 2020, 8 (03) :172-184

[7]

Ferrario Carlos M, 2016, Ther Adv Cardiovasc Dis, V10, P162, DOI 10.1177/1753944716642677

[8]

Funder John W, 2017, F1000Res, V6, P1738, DOI 10.12688/f1000research.11887.1

[9] The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline [J].

Funder, John W. ;

Carey, Robert M. ;

Mantero, Franco ;

Murad, M. Hassan ;

Reincke, Martin ;

Shibata, Hirotaka ;

Stowasser, Michael ;

Young, William F., Jr. .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2016, 101 (05) :1889-1916

[10] Mineralocorticoid receptor antagonists: emerging roles in cardiovascular medicine [J].

Funder, John W. .

INTEGRATED BLOOD PRESSURE CONTROL, 2013, 6 :129-138

← 1 2 3 4 5 →